{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:25:14Z","timestamp":1768566314539,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2005,6,1]]},"DOI":"10.1038\/sj.pcan.4500799","type":"journal-article","created":{"date-parts":[[2005,6,2]],"date-time":"2005-06-02T08:17:50Z","timestamp":1117700270000},"page":"194-200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Bicalutamide (\u2018Casodex\u2019) 150\u2009mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1\u2009y) in the early prostate cancer programme"],"prefix":"10.1038","volume":"8","author":[{"given":"M","family":"Wirth","sequence":"first","affiliation":[]},{"given":"C","family":"Tyrrell","sequence":"additional","affiliation":[]},{"given":"K","family":"Delaere","sequence":"additional","affiliation":[]},{"given":"M","family":"S\u00e1nchez-Chapado","sequence":"additional","affiliation":[]},{"given":"J","family":"Ramon","sequence":"additional","affiliation":[]},{"given":"D M A","family":"Wallace","sequence":"additional","affiliation":[]},{"given":"J","family":"Hetherington","sequence":"additional","affiliation":[]},{"given":"F","family":"Pina","sequence":"additional","affiliation":[]},{"given":"C","family":"Heyns","sequence":"additional","affiliation":[]},{"given":"T","family":"Borchers","sequence":"additional","affiliation":[]},{"given":"T","family":"Morris","sequence":"additional","affiliation":[]},{"given":"J","family":"Armstrong","sequence":"additional","affiliation":[]},{"name":"on behalf of the \u2018Casodex\u2019 Early Prostate Cancer Trialists' Group","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2005,6,2]]},"reference":[{"issue":"Suppl 6A","key":"BF4500799_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0090-4295(99)00448-3","volume":"54","author":"JA Smith Jr","year":"1999","unstructured":"Smith Jr JA, Soloway MS, Young MJ . Complications of advanced prostate cancer. Urology 1999; 54 (Suppl 6A): 8\u201314.","journal-title":"Urology"},{"key":"BF4500799_CR2","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0959-8049(03)00309-5","volume":"39","author":"C Pitceathly","year":"2003","unstructured":"Pitceathly C, Maguire P . The psychological impact of cancer on patients' partners and other key relatives: a review. Eur J Cancer 2003; 39: 1517\u20131524.","journal-title":"Eur J Cancer"},{"key":"BF4500799_CR3","first-page":"438","volume":"22","author":"BD Rosenfeld","year":"2003","unstructured":"Rosenfeld BD et al. Differences in health-related quality of life of prostate cancer patients based on disease stage. Proc Am Soc Clin Oncol 2003; 22: 438; abstract 1758.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF4500799_CR4","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1097\/01.ju.0000127732.63726.4c","volume":"171","author":"DF Penson","year":"2004","unstructured":"Penson DF et al. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol 2004; 171: 2250\u20132254.","journal-title":"J Urol"},{"key":"BF4500799_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0022-5347(05)64652-6","volume":"168","author":"WA See","year":"2002","unstructured":"See WA et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002; 168: 429\u2013435.","journal-title":"J Urol"},{"key":"BF4500799_CR6","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1097\/01.ju.0000140159.94703.80","volume":"172","author":"MP Wirth","year":"2004","unstructured":"Wirth MP et al. Bicalutamide 150\u2009mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median follow up of 5.4 years. J Urol 2004; 172: 1865\u20131870.","journal-title":"J Urol"},{"key":"BF4500799_CR7","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1097\/01.ju.0000139719.99825.54","volume":"172","author":"P Iversen","year":"2004","unstructured":"Iversen P et al. Bicalutamide (150\u2009mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group study number 6. J Urol 2004; 172: 1871\u20131876.","journal-title":"J Urol"},{"key":"BF4500799_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0090-4295(01)01213-4","volume":"58","author":"M Wirth","year":"2001","unstructured":"Wirth M et al. Bicalutamide (Casodex) 150\u2009mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001; 58: 146\u2013151.","journal-title":"Urology"},{"issue":"Suppl 3","key":"BF4500799_CR9","first-page":"220","volume":"86","author":"D Kirk","year":"2000","unstructured":"Kirk D, on behalf of the Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? BJU Int 2000; 86 (Suppl 3): 220; abstract MP6.1.07.","journal-title":"BJU Int"},{"key":"BF4500799_CR10","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/01.ju.0000053243.87457.60","volume":"169","author":"PM Ullrich","year":"2003","unstructured":"Ullrich PM et al. Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. J Urol 2003; 169: 1449\u20131452.","journal-title":"J Urol"},{"key":"BF4500799_CR11","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/S0022-5347(05)65657-1","volume":"166","author":"AL Zietman","year":"2001","unstructured":"Zietman AL et al. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol 2001; 166: 1702\u20131706.","journal-title":"J Urol"},{"key":"BF4500799_CR12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1524-4733.2004.74010.x","volume":"7","author":"K Moeremans","year":"2004","unstructured":"Moeremans K, Caekelbergh K, Annemans L . Cost-effectiveness analysis of bicalutamide (Casodex\u2122) for adjuvant treatment of early prostate cancer. Value Health 2004; 7: 472\u2013481.","journal-title":"Value Health"},{"key":"BF4500799_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","volume":"360","author":"M Bolla","year":"2002","unstructured":"Bolla M et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103\u2013108.","journal-title":"Lancet"},{"key":"BF4500799_CR14","first-page":"396","volume":"169","author":"E Messing","year":"2003","unstructured":"Messing E et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. J Urol 2003; 169: 396; abstract 1480.","journal-title":"J Urol"},{"key":"BF4500799_CR15","first-page":"381","volume":"22","author":"MV Pilepich","year":"2003","unstructured":"Pilepich MV et al. Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Proc Am Soc Clin Oncol 2003; 22: 381; abstract 1530.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF4500799_CR16","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0022-5347(05)67032-2","volume":"164","author":"P Iversen","year":"2000","unstructured":"Iversen P et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol 2000; 164: 1579\u20131582.","journal-title":"J Urol"},{"key":"BF4500799_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","volume":"163","author":"HW Daniell","year":"2000","unstructured":"Daniell HW et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181\u2013186.","journal-title":"J Urol"},{"key":"BF4500799_CR18","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1097\/01.ju.0000127738.94221.da","volume":"171","author":"PR Sieber","year":"2004","unstructured":"Sieber PR et al. Bicalutamide 150\u2009mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171: 2272\u20132276.","journal-title":"J Urol"},{"key":"BF4500799_CR19","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","volume":"22","author":"MR Smith","year":"2004","unstructured":"Smith MR et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004; 22: 2546\u20132553.","journal-title":"J Clin Oncol"},{"key":"BF4500799_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S0022-5347(18)38306-X","volume":"171","author":"AC Eaton","year":"2004","unstructured":"Eaton AC, Makris A, Makris A . Once weekly tamoxifen in the prevention of gynaecomastia and breast pain secondary to bicalutamide therapy. J Urol 2004; 171: 282; abstract 1069.","journal-title":"J Urol"},{"key":"BF4500799_CR21","first-page":"400","volume":"22","author":"F Boccardo","year":"2003","unstructured":"Boccardo F et al. Tamoxifen (T) is more effective than anastrozole (A) in preventing gynecomastia induced by bicalutamide (B) monotherapy in prostate cancer (pca) patients (pts). Proc Am Soc Clin Oncol 2003; 22: 400; abstract 1608.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF4500799_CR22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ijrobp.2004.03.022","volume":"60","author":"CJ Tyrrell","year":"2004","unstructured":"Tyrrell CJ et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10\u2009Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 2004; 60: 476\u2013483.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 5","key":"BF4500799_CR23","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.1016\/S1359-6349(03)90907-4","volume":"1","author":"H Van Poppel","year":"2003","unstructured":"Van Poppel H et al. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced breast pain and gynaecomastia in prostate cancer. Eur J Cancer 2003; 1 (Suppl 5): S265; abstract 881.","journal-title":"Eur J Cancer"},{"key":"BF4500799_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S1569-9056(04)90224-2","volume":"3","author":"M Wirth","year":"2004","unstructured":"Wirth M et al. Response to second-line hormonal therapy following progression on bicalutamide (\u2018Casodex\u2019) 150\u2009mg monotherapy. Eur Urol Suppl 2004; 3: 58; abstract 223.","journal-title":"Eur Urol Suppl"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/4500799.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/4500799","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/4500799.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T18:54:42Z","timestamp":1648666482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/4500799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,1]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6,1]]}},"alternative-id":["BF4500799"],"URL":"https:\/\/doi.org\/10.1038\/sj.pcan.4500799","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,1]]},"assertion":[{"value":"1 March 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}